user

Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)

被引：0
|
作者：
Jagannath, Sundar
Lee, Hans C.
Richter, Joshua Ryan
Zonder, Jeffrey A.
Hoffman, James E.
Zhou, Zheng-Yi
Horton, Viviana Garcia
Fillbrunn, Mirko
Wang, Hongjue
Mattera, Matthew
Ma, Qiufei
Inocencio, Timothy J.
Xu, Yingxin
Bergrath, Evelien
Harnett, James
Roccia, Tito
Kroog, Glenn Scott
Rodriguez-Lorenc, Karen
Houvras, Yariv
Bumma, Naresh
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA
[3] Karmanos Canc Inst, Detroit, MI USA
[4] Univ Miami Hlth Syst, Miami, FL USA
[5] Anal Grp Inc, Boston, MA USA
[6] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[7] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7560
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG Sites
    Kumar, Shaji
    Jagannath, Sundar
    Weisel, Katja C.
    Dachs, Laura Rosinol
    Dimopoulos, Meletios-Athanasios
    Siegel, David S.
    Monge, Jorge
    Leleu, Xavier
    Du, Juan
    de la Rubia, Javier
    Lee, Jae Hoon
    Mateos, Maria-Victoria
    Gozzetti, Alessandro
    Dytfeld, Dominik
    Ocio, Enrique M.
    Blade, Joan
    Ozaki, Shuji
    Nagaraj, Madhu
    Hassan, Rafla
    Green, Jeannette
    Kroog, Glenn S.
    Lorenc, Karen Rodriguez
    Hampp, Christian
    Ma, Qiufei
    Durie, Brian G. M.
    BLOOD, 2024, 144 : 7039 - 7041
  • [32] Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma
    Shah, Nina
    Mojebi, Ali
    Ayers, Dieter
    Cope, Shannon
    Dhanasiri, Sujith
    Davies, Faith E.
    Hari, Parameswaran
    Patel, Payal
    Hege, Kristen
    Dhanda, Devender
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022, 11 (10) : 737 - 749
  • [33] Practice patterns and outcomes for triple-class exposed patients with relapsed/refractory multiple myeloma in Japan
    Iida, Shinsuke
    Nakakoji, Mayuko
    Spanopoulos, Dionysis
    Okazuka, Kiyoshi
    Parulekar, Vipul
    Ishida, Tadao
    FUTURE ONCOLOGY, 2022, 18 (34) : 3839 - 3852
  • [34] CAR T-cell therapy for triple-class exposed relapsed/refractory multiple myeloma
    Cavo, Michele
    HAEMATOLOGICA, 2023, 108 (08) : 1988 - 1990
  • [35] CHARACTERISTICS AND TREATMENT PATTERNS OF MEDICARE BENEFICIARIES WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Hlavacek, P.
    Silverstein, A.
    Petrilla, A.
    Leinwand, B., I
    Johnson, W.
    Schroeder, A.
    VALUE IN HEALTH, 2022, 25 (07) : S486 - S487
  • [36] Standard of care (SOC) outcomes in the last 3 years in patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM): the first pooled analysis of LocoMMotion and MoMMent trials
    Weisel, Katja
    Mateos, Maria-Victoria
    Gonzalez Garcia, Maria Esther
    Bittrich, Max
    Lindsey-Hill, Joanne
    De Stefano, Valerio
    Besemer, Britta
    Vincent, Laure
    Kirkpatrick, Suriya
    Karlin, Lionel
    Goldschmidt, Hartmut
    Conticello, Concetta
    Roeloffzen, Wilfried
    van de Donk, Niels
    Delforge, Michel
    Doyle, Margaret
    Gray, Kathleen
    Albrecht, Claire
    Strulev, Vadim
    Haddad, Imene
    Saarinen, Silva
    Mitchell, Lada
    Buyze, Jozefien
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S217 - S218
  • [37] Talquetamab vs real-world physician′s choice of therapy (RWPC): comparative efficacy in patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
    Ye, Jing Christine
    Biran, Noa
    Nair, Sandhya
    Lin, Xiwu
    Qi, Keqin
    Londhe, Anil
    Ammann, Eric
    Renaud, Thomas
    Kane, Colleen
    Parekh, Trilok
    Gray, Kathleen
    Peterson, Steve
    Costa, Luciano
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S219 - S220
  • [38] Real-Life Outcomes in Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Carfilzomib-and/or Pomalidomide-Based Regimens in the LocoMMotion and MoMMent Studies
    Mateos Manteca, Maria-Victoria
    Weisel, Katja
    Gonzalez Garcia, Maria Esther
    Einsele, Hermann
    Lindsey-Hill, Joanne
    De Stefano, Valerio
    Besemer, Britta
    Vincent, Laure
    Kirkpatrick, Suriya
    Karlin, Lionel
    Goldschmidt, Hartmut
    Conticello, Concetta
    Roeloffzen, Wilfried
    van de Donk, Niels
    Delforge, Michel
    Villanova, Pamella
    Doyle, Margaret
    Gray, Kathleen
    Albrecht, Claire
    Strulev, Vadim
    Buyze, Jozefien
    Squire, Jonathan
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S270 - S271
  • [39] Adjusted comparison of teclistamab versus physician's choice of therapy in the long-term follow-up of daratumumab trials in patients with triple-class exposed relapsed or refractory multiple myeloma
    Mateos, Maria-Victoria
    Chari, Ajai
    Usmani, Saad
    Goldschmidt, Hartmut
    Weisel, Katja
    Qi, Keqin
    Londhe, Anil
    Nair, Sandhya
    Lin, Xiwu
    Pei, Lixia
    Ammann, Eric
    Kobos, Rachel
    Smit, Jennifer
    Parekh, Trilok
    Marshall, Alexander
    Slavcev, Mary
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S192 - S193
  • [40] Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma
    Mancuso, Katia
    Barbato, Simona
    Talarico, Marco
    Tacchetti, Paola
    Zamagni, Elena
    Cavo, Michele
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2025, 25 (01) : 27 - 46
12345